Published in Cancer Weekly, December 16th, 2003
Plk1 plays a central role in the regulation of the cancer cell cycle at the stage of mitosis or cell division. David Glover, chief scientist of Cyclacel's Polgen division, first discovered Plk in 1988. The Plk1 inhibitors were discovered using Cyclacel's state-of-the-art rational drug design technology.
Spiro Rombotis, CEO of Cyclacel said, "The Plk1 inhibitors are the latest additions to our growing pipeline of cell cycle modulators, which includes clinical,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.